Efficacy of intramuscular polysulfated glycosaminoglycan in a controlled study of equine carpitis.

This research study expounds on the effectiveness of intramuscular polysulfated glycosaminoglycan (PSGAG) in treating horse arthritis, specifically carpitis. The results suggest that PSGAG reduces joint swelling and lameness, and enhances carpal flexion in horses with chemically induced carpitis more than treatment with normal saline.

Research Methodology

• The researchers used 12 healthy horses and subjected them to the monoioidoacetate (MIA) carpitis model to induce carpitis, a condition characterized by inflammation of the joints. The inflammation was allowed to develop for seven days.
• After the inflammation had set in, the horses were randomly divided into two groups. Group A served as the control group and received an intramuscular injection of normal saline every four days for seven treatments. On the other hand, Group B received 500 mg of PSGAG intramuscularly every four days, also for seven treatments.

Evaluation and Results

• The effectiveness of PSGAG was assessed by three clinical outcomes: lameness score, carpal circumference (which measures joint swelling), and maximum carpal flexion (which measures the degree of bending at the joint). These outcomes were measured at various points in the study: prior to inducing carpitis, prior to drug treatment, and on days 7, 14, 21, 28, and 35.
• The data was then plotted (clinical outcome against time) to create areas under the curve which were then used as variables for statistical analysis.
• The results showed less joint circumference enlargement (signaling less inflammation) and lameness, and greater carpal flexion (signifying better joint movement) in PSGAG-treated horses compared to the control group.

Conclusion

• The researchers concluded that PSGAG has a positive effect on the treatment of chemically induced carpitis in horses. They inferred that this compound could potentially be a useful treatment for equine arthritis.